| Accession Number | 0001193125-26-335820 |
|---|---|
| Form Type | 4 |
| Filing Date | Aug 5, 2026 |
| Document | View SEC Filing |
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
SVP, Drug Discovery | Common Stock | โ | Aug 3, 2026 | Exercise/Conversion | 1,816 | $2.76 | $5,012.16 | 98,228 | Direct | โ | View Details | |
SVP, Drug Discovery | Common Stock | โ | Aug 3, 2026 | Exercise/Conversion | 1,518 | $2.76 | $4,189.68 | 99,746 | Direct | โ | View Details | |
SVP, Drug Discovery | Common Stock | โ | Aug 3, 2026 | Sale | 1,000 | $33.98 | $33,975.60 | 98,746 | Direct | โ | View Details | |
SVP, Drug Discovery | Common Stock | โ | Aug 3, 2026 | Sale | 2,334 | $34.68 | $80,944.29 | 96,412 | Direct | โ | View Details | |
SVP, Drug Discovery | Stock Option (Right to Buy) | Derivative | Aug 3, 2026 | Exercise/Conversion | 1,816 | $0.00 | $0.00 | 5,227 | Direct | โ | View Details | |
SVP, Drug Discovery | Stock Option (Right to Buy) | Derivative | Aug 3, 2026 | Exercise/Conversion | 1,518 | $0.00 | $0.00 | 12,418 | Direct | โ | View Details |